방법 비교
선택한 방법을 나란히 검토하세요. 서로 다른 행은 강조 표시됩니다.
| 장애 보정 생명 연수 (DALY)× | 비용효과 분석 (CEA)× | |
|---|---|---|
| 분야 | 보건경제학 | 보건경제학 |
| 계열 | Process / pipeline | Process / pipeline |
| 기원 연도≠ | 1990 | 1984 |
| 창시자≠ | Christopher J. L. Murray and Alan D. Lopez (World Health Organization / World Bank) | Drummond & Stoddart (Health Economics Research Group, McMaster University) |
| 유형 | Method | Method |
| 원전≠ | Murray, C. J., Lopez, A. D., & Jamison, D. T. (1994). The Global Burden of Disease in 1990: Summary Results, Sensitivity Analysis, and Future Directions. In C. J. Murray & A. D. Lopez (Eds.), Global Burden of Disease and Injury. Cambridge: Harvard University Press. link ↗ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. link ↗ |
| 별칭 | DALY, global disease burden metric, burden of disease | CEA, ICER, Incremental Cost-Effectiveness Ratio |
| 관련 | 5 | 5 |
| 요약≠ | A DALY quantifies disease burden as the sum of years of life lost to premature death and years lived with disability. Developed by the World Health Organization and World Bank in 1990 as part of the Global Burden of Disease (GBD) study, DALYs enable epidemiologists and public health planners to compare disease burden across populations, identify health priorities, and evaluate intervention impact. One DALY = one lost year of 'healthy' life; DALYs averted measure progress toward health goals. | Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price. |
| ScholarGate데이터셋 ↗ |
|
|